United States Antimicrobial Susceptibility Testing Market 2026 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

The Global Antimicrobial Susceptibility Testing Market reached US$ 3,467.54 million in 2023 and is expected to reach US$ 5,430.20 billion by 2031, growing at a CAGR of 5.9% during the forecast period 2024-2031.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/antimicrobial-susceptibility-testing-market?sb

Key Development:

United States: Recent Industry Developments

✅ In February 2026, the U.S. FDA updated recognized antimicrobial susceptibility testing interpretive criteria to improve accuracy in evaluating bacterial resistance patterns. The update strengthens clinical laboratory decision-making and supports faster selection of targeted antibiotic therapies. It enhances nationwide antimicrobial stewardship initiatives against rising resistance threats.

✅ In January 2026, CARB-X expanded funding support for QuantaMatrix's rapid diagnostic platform designed to accelerate antimicrobial susceptibility testing for neonatal sepsis detection. The investment aims to enable earlier intervention and improve survival outcomes through faster resistance identification. It reinforces U.S. innovation in rapid AST diagnostics.

✅ In December 2025, the FDA recognized updated CLSI antimicrobial susceptibility breakpoints, enabling laboratories to adopt standardized resistance interpretation aligned with evolving bacterial profiles. The recognition improves consistency across diagnostic workflows and antimicrobial drug development programs. It supports more precise antibiotic treatment decisions nationwide.

✅ In December 2025, U.S. clinical microbiology initiatives advanced adoption of rapid phenotypic antimicrobial susceptibility testing technologies designed to shorten diagnostic timelines and optimize targeted therapy selection. The developments focus on reducing reliance on broad-spectrum antibiotics. They strengthen hospital infection management and antimicrobial resistance control strategies.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=antimicrobial-susceptibility-testing-market

Japan: Recent Industry Developments

✅ In February 2026, Japanese diagnostic laboratories accelerated adoption of AI-enabled antimicrobial susceptibility testing platforms to improve diagnostic precision and automate resistance detection workflows. The integration enhances laboratory efficiency and supports faster clinical decision-making. It reflects Japan's push toward intelligent diagnostic infrastructure.

✅ In January 2026, Japanese healthcare stakeholders expanded investments in advanced diagnostic testing technologies, including rapid microbiology and susceptibility testing systems, to address increasing antimicrobial resistance challenges. The initiative strengthens hospital laboratory capabilities nationwide. It supports early and targeted infection treatment strategies.

✅ In December 2025, Japanese research programs advanced automated antimicrobial susceptibility testing systems integrating digital analytics for standardized laboratory workflows. The development improves reproducibility and reduces manual testing variability. It enhances precision-focused diagnostics across clinical settings.

✅ In December 2025, collaborative research efforts in Japan promoted next-generation rapid AST methodologies combining molecular diagnostics and automation technologies. The initiatives aim to deliver same-day antibiotic guidance and improve antimicrobial stewardship outcomes. They support national efforts to combat antimicrobial resistance.

Key Players:

=> bioMérieux S.A., Danaher Corporation, Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Merck Group, HiMedia Laboratories, Alifax Holding S.p.A., Creative Diagnostics, and Synbiosis, among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/antimicrobial-susceptibility-testing-market?sb

Key Segments:

By Product Type

Manual Antimicrobial Susceptibility Testing Products account for 18% share, driven by continued use in small laboratories and cost-sensitive healthcare settings.

Susceptibility Testing Disks hold 16%, supported by widespread adoption of disk diffusion testing due to simplicity and affordability.

MIC Strips represent 14%, gaining traction for providing accurate minimum inhibitory concentration measurements in clinical diagnostics.

Susceptibility Plates capture 12%, used extensively in standardized laboratory workflows and research applications.

Automated Laboratory Instruments dominate with 25% share, fueled by increasing demand for high-throughput testing, automation, and faster diagnostic turnaround.

Consumables account for 15%, supported by recurring demand from routine antimicrobial testing procedures.

By Method

Broth Dilution Method leads with 24% share, considered a gold standard for precise antimicrobial susceptibility evaluation.

Rapid Automated Method holds 28%, driven by increasing laboratory automation and need for rapid clinical decision-making.

Disk Diffusion Method accounts for 20%, widely used due to cost efficiency and standardized testing protocols.

Gradient Diffusion Method represents 16%, preferred for accurate MIC determination in specialized testing environments.

Molecular Testing Method captures 12%, expanding rapidly with advancements in molecular diagnostics and resistance gene detection.

By Test Type

Antibacterial Testing dominates with 58% share, owing to rising antimicrobial resistance and increasing bacterial infection prevalence worldwide.

Antifungal Testing holds 22%, supported by growing incidence of fungal infections among immunocompromised patients.

Antiparasitics Testing accounts for 12%, driven by continued monitoring of parasitic diseases in developing regions.

Others represent 8%, covering emerging pathogen testing applications.

By Application

Clinical Diagnosis leads with 64% share, driven by increasing hospital testing volumes and demand for targeted antimicrobial therapies.

Drug Discovery and Development accounts for 26%, supported by pharmaceutical R&D efforts focused on new antimicrobial agents.

Others hold 10%, including surveillance and epidemiological research activities.

By End User

Diagnostic Centers and Hospitals dominate with 52% share, supported by rising infection testing and antimicrobial stewardship programs.

Pharmaceutical and Biotechnology Companies account for 20%, driven by antimicrobial drug development initiatives.

Contract Research Organizations (CROs) hold 15%, benefiting from outsourcing of laboratory testing services.

Research and Academic Institutes represent 13%, supported by increasing microbiology and resistance research activities.

By Region

North America leads with 35% share, attributed to advanced laboratory infrastructure and strong antimicrobial resistance monitoring programs.

Europe accounts for 27%, supported by regulatory initiatives promoting antimicrobial surveillance.

Asia Pacific holds 23%, driven by expanding healthcare systems and increasing infectious disease burden.

Latin America represents 8%, reflecting improving diagnostic adoption.

Middle East & Africa capture 7%, supported by growing healthcare investments and infection control initiatives.

Outlook & Opportunity Analysis (2024-2031)

The antimicrobial susceptibility testing market is expected to grow steadily due to rising antimicrobial resistance (AMR), increasing infectious disease prevalence, and growing adoption of automated diagnostic systems. Key opportunities lie in rapid molecular diagnostics, AI-enabled laboratory automation, and expansion of testing infrastructure across emerging economies, particularly in Asia Pacific and Middle East & Africa.

FAQ

What is the current size of the Antimicrobial Susceptibility Testing Market?

A: In 2023, the Antimicrobial Susceptibility Testing Market was valued at US$ 3,467.54 million, reflecting its strong industry presence.

Q2: How large is the Antimicrobial Susceptibility Testing Market expected to be by 2031?

A: By 2031, industry forecasts suggest the Antimicrobial Susceptibility Testing Market will grow to around US$ 5,430.20 billion, demonstrating significant expansion.

Q3: What is the growth rate of the Antimicrobial Susceptibility Testing Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 5.9% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.